Biotec Pharmacon’s subsidiary, ArcticZymes, granted €254.000 funding from Eurostars for a synthetic biology project

Tromsø, Norway, 2. April 2019 – Biotec Pharmacon (OSE: Biotec) announced today that its subsidiary, ArcticZymes, has been granted €254k as part of a collaborative project on the development of novel enzymes for synthetic biology.

The project proposal was developed in collaboration with the University of Tromsø and Danish company, Legomics, has been positively evaluated by the Eurostars programme. ArcticZymes is to participate in developing novel DNA ligases, enabling novel chemistry for synthetizing DNA and genes to be further developed by Legomics.

Working alongside the University of Tromsø, ArcticZymes have used Arctic marine bioprospecting and engineering to establish a substantial base for the development of enzymes with novel unique properties.

ArcticZymes Managing Director Jethro Holter said:

“This project supports ArcticZymes ambitions towards building a broader synergistic product portfolio, with wide applicability across all three molecular biology market segments it serves – research, IVD and therapeutics. We are also excited to partner with Legomics and the University of Tromsø in enabling a novel gene synthesis technology.”

Christian Jørgensen, CEO, added:

“The project will further strengthen our long-term collaboration with the University of Tromsø in the discovery of other classes of unique enzymes. Furthermore, we are looking forward to establishing a closer relationship with Legomics and developing enzyme technology for use in gene synthesis technology and various other applications.”


For more information, please contact:
Biotec Pharmacon
Christian Jørgensen, CEO                                           Tel: +47 47 79 24 57
Jethro Holter, MD ArcticZymes                                    Tel: + 47 46 85 91 46

Instinctif Partners
Melanie Toyne-Sewell / Dr Christelle Kerouedan /       Tel: +44 207 457 2020 
Deborah Bell